Dar Bioscience Inc Revenue Growth Rates (DARE), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Dar Bioscience Inc   (NASDAQ: DARE)
 

DARE's Revenue Growth by Quarter and Year

Dar Bioscience Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DARE Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 0.19
1st Quarter March 0.15
FY 0.34





DARE Revenue second quarter 2026 Y/Y Growth Comment
Dar Bioscience Inc in the second quarter 2026 achieved Revenue of $ 0.19 millions compare to recorded in same quarter a year ago.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 42 other companies have achieved higher Revenue growth. While Dar Bioscience Inc ' s Revenue no change of 0% ranks overall at the positon no. 399 in the second quarter 2026.


DARE Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - - - -
3rd Quarter September - - -96 % -
2nd Quarter June - - - -
1st Quarter March 400 % 200 % - -
FY   - - - -

Financial Statements
Dar Bioscience Inc 's second quarter 2026 Revenue $ 0.19 millions DARE's Income Statement
Dar Bioscience Inc 's second quarter 2025 Revenue $ 0.00 millions Quarterly DARE's Income Statement


DARE Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - - - 81 %
3rd Quarter September - - 100 % -
2nd Quarter June 25.03 % - 100 % -
1st Quarter March -85 % - -99.45 % -
FY (Year on Year)   - - - -


Back to DARE Growth rate Comparisons >> Back to DARE Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #43
Healthcare Sector #90
Overall #399

Revenue Y/Y Growth Statistics
High Average Low
44219.36 % 2975.26 % -100 %
(Dec 31 2025)   (Jun 30 2025)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #43
Healthcare Sector #90
Overall #399
Revenue Y/Y Growth Statistics
High Average Low
44219.36 % 2975.26 % -100 %
(Dec 31 2025)   (Jun 30 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Dar Bioscience Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
44219.36 % 2975.26 % -100 %
(Dec 31 2025)  


DARE's II. Quarter Q/Q Revenue Comment
Dar Bioscience Inc achieved in the II. Quarter 2026 below company average Revenue jump of 25.03% quarter on quarter, to $ 0.19 millions.

Although the II. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the II. Quarter surge, eclipses the % growth in the II. Quarter a year ago

Within Major Pharmaceutical Preparations industry 42 other companies have achieved higher Revenue quarter on quarter growth. While Dar Bioscience Inc 's Revenue growth quarter on quarter, overall rank is 399.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #43
Healthcare Sector #90
Overall #399
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #43
Healthcare Sector #90
Overall #399
Revenue Q/Q Growth Statistics
High Average Low
44219.36 % 2975.26 % -100 %
(Dec 31 2025)  


DARE's II. Quarter Q/Q Revenue Comment
Dar Bioscience Inc achieved in the II. Quarter 2026 below company average Revenue jump of 25.03% quarter on quarter, to $ 0.19 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the % in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 42 other companies have achieved higher Revenue quarter on quarter growth. While Dar Bioscience Inc 's Revenue growth quarter on quarter, overall rank is 399.


Dar Bioscience Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 1.34 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment


Dar Bioscience Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment


Dar Bioscience Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
DARE's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Seer Inc -0.29%$ -0.289 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions
Adapthealth Corp -7.50%$ -7.505 millions
China Pharma Holdings Inc-7.55%$ -7.548 millions
Skinhealth Systems Inc -7.68%$ -7.680 millions


About Dar Bioscience Inc Revenue Growth Rates (DARE), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Dare Bioscience Inc (CIK 1401914).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001401914-26-000043
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Dare Bioscience Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.